Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)

NCT05047185 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT05047185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05047185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 2
Overall status
Terminated
Start date
April 19, 2022
Completion date
June 30, 2025
Enrollment
34 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

c1 esterase inhibitor deficiency, c1 inhibitor deficiency, hereditary angioedema, hereditary angioedema - type 1, hereditary angioedema - type 2, hereditary angioedema attack, hereditary angioedema type i, hereditary angioedema type ii, hereditary angioedema types i and ii, hereditary angioedema with c1 esterase inhibitor deficiency